Matinas BioPharma Holdings (MTNB) Cash from Investing Activities (2013 - 2025)
Matinas BioPharma Holdings (MTNB) reported Cash from Investing Activities of $15000.0 for Q4 2025, down 97.0% year-over-year from $500000.0 in Q4 2024, and down 97.0% quarter-over-quarter from $500000.0 in Q4 2024.
Matinas BioPharma Holdings (MTNB) Cash from Investing Activities (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 12 years of Cash from Investing Activities data on file, last reported at $15000.0 in Q4 2025.
- Cash from Investing Activities for Q4 2025 came in at $15000.0, down 97.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.2 million (down 21.56% YoY), and the FY2025 annual result was $335000.0, down 96.36% from the prior year.
- Cash from Investing Activities declined to $15000.0 in Q4 2025 per MTNB's latest filing, from $500000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $9.6 million in Q3 2024 and troughed at -$3.8 million in Q2 2022.
- A 5-year average of $2.6 million and a median of $2.0 million in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 174.14% in 2022, then jumped 7147.62% in 2023.
- A 5-year view of Cash from Investing Activities shows it stood at $56653.0 in 2021, then tumbled by 174.14% to -$42000.0 in 2022, then jumped by 7147.62% to $3.0 million in 2023, then slumped by 83.11% to $500000.0 in 2024, then slumped by 97.0% to $15000.0 in 2025.
- Business Quant data shows MTNB's Cash from Investing Activities at $15000.0 in Q4 2025, $500000.0 in Q4 2024, and $9.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 9.65 Mn |
| Sep 30, 2024 | 9.65 Mn |
| Jun 30, 2024 | -2.94 Mn |
| Jun 30, 2024 | -2.94 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 2.96 Mn |
| Dec 31, 2023 | 2.96 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 6.20 Mn |
| Jun 30, 2023 | 6.20 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Dec 31, 2022 | -42,000.00 |
| Dec 31, 2022 | -42,000.00 |